Abstract: In biliary atresia (BA), a cholangiopathy of elusive etiology invariably leads to cirrhosis, and a disturbed angiogenesis may be involved. We evaluated the hepatobiliary immunolocalization of vascular endothelial growth factor (VEGF) A, VEGF receptor 1 (R1), and R2 in BA. We analyzed biopsies obtained at portoenterostomy from infants with BA (n = 52), including embryonic (n = 14) and perinatal (n = 38) types. Controls were infants with intrahepatic cholestasis (IC; n = 7). In BA, VEGF A immunolocalization was also evaluated in explants (n = 33) and at the porta hepatis (n = 16). We morphometrically assessed the percentage of CK7 (PCK7) positivity in BA and the ratio medial layer thickness/luminal diameter in hepatic artery branches in BA and IC. We found that arteries were more frequently positive for VEGF A in BA at portoenterostomy (P = 0.006) than in other groups. In explants, VEGF A immunolocalization was mainly lobular (P<0.001). VEGFR2 was less frequently positive in BA than IC in bile ducts (P = 0.023) and hepatocytes (P = 0.011). A higher PCK7 positivity was associated with arterial (P<0.001) and biliary (P = 0.040) VEGF A positivity. PCK7 was correlated with biliary (P = 0.031), arterial (P = 0.031), and hepatocytic (P = 0.032) VEGF A positivity in BA at portoenterostomy. VEGF A was positive in arteries and bile ducts at the porta hepatis mainly in the perinatal BA type (P = 0.013). Biliary (P = 0.016) and arterial (P = 0.044) VEGF A positivity were associated with higher ratio medial layer thickness/luminal diameter values. Our findings suggest that hypoxia/ischemia affects the portal structures in BA at portoenterostomy, beginning at the porta hepatis, and it is associated both with the extent of biliary proliferation and medial layer thickening.
B
iliary atresia (BA) is an infantile disorder, which is characterized by the complete obstruction of a portion or the entirety of the extrahepatic bile ducts (BDs). Regardless of timely performance of portoenterostomy, the surgical procedure that removes the impediment to biliary flow, all (or almost all) patients with BA experience progressive derangement of the intrahepatic biliary system, leading to increasing fibrogenesis and eventually to cirrhosis. 1 The cause of this progressive cholangiopathy remains elusive, 2, 3 and BA is the main indication for liver transplantation (LTx) in children. 4 The BA phenotype seemingly results from the interplay between environmental and genetic factors. The contribution of genetic factors is suggested by the coexistence of congenital extrahepatic malformations (EHM), including laterality defects, in a subgroup of infants with BA, the embryonic clinical type, in contrast with the perinatal form. 5 BA histopathology is characterized by dynamic age-dependent changes, 6 including biliary proliferation, evident at around the sixth week of life and associated with peribiliary fibrogenesis. At approximately the 16th week, because of a continuous biliary epithelial degeneration, biliary proliferation is followed by disappearance of interlobular BDs and, over time, BA becomes a disorder of paucity of BDs. 7 Among the clinical and histopathological variables that influence survival of the native liver after portoenterostomy, such as age at the time of portoenterostomy 8, 9 and fibrosis extent, 10 our group observed that a greater extent of biliary proliferation was a detrimental factor. 11 Our group has also described the presence of arterial medial layer thickening, progressive from portoenterostomy until LTx, apparently associated with the vanishing of BDs, 12 and other groups have reinforced our findings as well. [13] [14] [15] [16] Our hypothesis is that vascular alterations in BA can be caused by disturbed angiogenesis. Beaussier et al, 17 using an animal model, described the pattern of immunolocalization for the angiogenic factor vascular endothelial growth factor (VEGF A) characteristic of a double ligation both in the common BD and in the peribiliary vascular plexus that nourishes 
MATERIALS AND METHODS

Patients
We analyzed the immunolocalization of VEGF A and its receptors in liver biopsies obtained at portoenterostomy from 52 infants (26 boys and 26 girls) with BA admitted to our institution between 1986 and 2007. The diagnosis of BA was based on laparotomy findings, operative cholangiography, and histology of portal BD remnants. Biopsies from patients with intrahepatic cholestasis (IC, n = 7), including a-1-antitrypsin deficiency (n = 2), idiopathic neonatal hepatitis (n = 4), and hypopituitarism (n = 1), were used as controls. VEGF A immunolocalization was also evaluated in the explants from 33 BA patients (17 18 BA splenic malformation in 6 cases and nonsyndromic type malformations in 8 cases. They consisted of the BA embryonic clinical type, whereas the remaining patients, without EHM, were included in the perinatal clinical type. In addition, we evaluated the VEGF A immunolocalization at the porta hepatis obtained at portoenterostomy from 16 infants with BA included in this study. The wedge liver biopsies were taken at the time of exploratory laparotomy from the anterior margin of segment IV using standard methods. Formalin-fixed paraffin-embedded specimens from the liver and the porta hepatis were examined. Five-micrometer thick sections were obtained and subjected to immunohistochemistry to label VEGF A (Santa Cruz Biotechnology Inc, Santa Cruz; 1:400), VEGFR1 (Epitomics, Burlingame; 1:100), VEGFR2 (Santa Cruz Biotechnology Inc, Santa Cruz; 1:200), antihuman-specific actin, clone HHF-35 (DAKO Corporation, Carpinteria; 1:100), and anticytokeratin 7 (CK7, DAKO A/S, Glostrup, Denmark; 1:100). Anti-HHF-35 was used to outline the arterial smooth muscle cells, aiming at analyzing the medial layer thickening. Anti-CK7, a marker of biliary epithelium, was used to outline biliary structures to assess the percentage of CK7 positivity (PCK7). Immunolabeling was amplified using the avidin-biotin peroxidase complex, as described earlier. 19 We used a multispecies reagent (EasyPath; Erviegas Ltd, Sa˜o Paulo, Brazil) as the secondary antibody. Negative tissue controls underwent the same immunohistochemical protocol, except for the use of the primary antibody. Alternate 5-mm thick sections were stained with Picrosirius red aiming to measure the collagen area (CA). All patients included in the study group were operated on by the same surgical team and were followed during hospitalization and in the outpatient clinic of our institution by the same clinicians.
Immunolocalization of VEGF A, VEGFR1, and R2
Immunolocalization of VEGF A, VEGFR1, and R2 included the specification of the hepatobiliary structures with positive expression of the markers in the study, performed simultaneously by a pathologist and a pediatric gastroenterologist, both with expertise in liver histopathology and in evaluation of immune stained specimens, and blinded regarding the clinical data. Adequate expression patterns for the markers were analyzed according to the protocol developed by Wu et al 20 as: 0-no staining, 1-light yellow staining, 2-dark yellow staining, and 3-brown staining with granular distribution. The positivity cut-off level was 2.
Morphometric Image Analysis
Morphometric image analysis consisted of evaluations of CA, PCK7, and the ratio arterial medial layer thickening/luminal diameter (RMED). From each slide, 10 images were captured from randomly selected highpower fields (magnification Â 200) containing Picrosirius, CK7, and HHF-35-positive structures and were saved in the TIFF format for later analysis. The halogen lamp voltage was kept constant through voltage stabilization. Picrosirius and CK7 staining were examined quantitatively. HHF-35, outlining the medial layer, helped the assessment of the vascular components, medial layer, and luminal diameter. Morphometric measurements were made using the Adobe Photoshop CS3 Extended 10.0 (Adobe Systems Inc, San Jose, CA) software on every biliary structure, on areas of positivity for collagen, and on arterial vessels in each image. For each patient, values obtained in every measurement of CA, PCK7, and RMED were registered, and the mean was calculated. In every morphometric activity, the histologic assessor was blinded to the clinical data.
PCK7
The PCK7 was assessed according to Santos et al, 11 and expressed the extent of biliary proliferation in liver biopsies at the time of portoenterostomy. In brief, every image exhibited on the monitor was adjusted to the same threshold level, and the area of CK7-positive structures was measured in pixels. The total amount of pixels per image remained constant in all fields. The PCK7 in each image was then calculated using the ratio of the CK7-positive area to the total amount of pixels per image.
CA
It was assessed as described earlier, 8 expressing the extent of tissue fibrosis at the time of portoenterostomy. CA was the mean, for each patient, of the ratio of the CA stained with Picrosirius red, measured in pixels, to the total amount of pixels per image. The areas of Picrosirius red positivity in portal spaces and in the fibrous septae were randomly selected, avoiding the subcapsular area, where increased fibrosis extent is normally found. The same background was subtracted in every image and, subsequently, the percentage of black was assessed.
RMED
RMED was based on the study by Santos et al, 12 and obtained by morphometric assessments of the arterial medial layer thickness and luminal diameter. Medial layer thickness was defined as a mean of 4 values of medial thickness obtained by a line drawn to the central axis and connecting 2 points, 1 at the outer and the second at the inner face of the medial layer. Luminal diameter was defined as the mean of 2 values of luminal diameter obtained by a line drawn connecting 2 points at luminal surface, 1 from the largest and the second from the smallest diameter.
Statistical Analysis
The findings were expressed as mean ± SD or interquartile range for quantitative variables and frequency and percentage for qualitative variables. Quantitative variables were compared using Student t test. Data presenting asymmetric distribution were analyzed by nonparametric tests. 
Ethics
The Research and Postgraduation Group Ethics Committee of the Hospital de Clı´nicas de Porto Alegre approved this study. Figure 1 shows the hepatobiliary structures that are positive for VEGF A in the livers of the patients in study.
RESULTS
The portal tract (Fig. 1A ) and porta hepatis (Fig.  1B) obtained from necropsy of a patient without liver disease expressed VEGF A in hepatocytes, not in the portal structures. In BA, at the time of portoenterostomy (Figs. 1C, D) , VEGF A was positive in arterial walls (AWs), BDs, besides hepatocytes; at the time of LTx (Fig.  1E ) VEGF A expression was located in the parenchyma. At the porta hepatis from patients with BA (Figs. 1F, G, 2F), VEGF A expression was positive in biliary remnants, AWs, and, when available for evaluation, in hepatocytes; additionally, some arteries presented a distorted morphology. Table 1 shows the comparison of the immunohistochemical positivity rates in hepatobiliary structures, according to the groups in study.
There were differences in VEGF A positivity rates among groups in 2 structures: AWs (P = 0.006) and hepatocytes (P<0.001). The VEGF A positivity rate in AWs was higher in biopsies from BA patients, mainly in the perinatal form, compared with IC and explants. On the contrary, hepatocytic VEGF A positivity rate was higher in explants. Positive patients were rare for VEGFR1 in AWs and BDs (Figs. 2A, B ). There was a difference among groups in the AW positivity rate (P = 0.048), which was lower in the BA perinatal form than in the BA embryonic form and IC.
The VEGFR2 positivity rate presented differences among groups in BDs (P = 0.023) and hepatocytes (P = 0.011), being higher, for both structures, in IC than in BA. VEGFR2 was positive for both structures in every IC patient, presenting lower positivity rates in BA. Figures 2C and D show the VEGFR2 immunostaining in patients with BA and IC, respectively.
At the porta hepatis, the VEGF A positivity rate in BDs was higher in the BA perinatal form (P = 0.013). Table 2 shows the relationship between the variables associated with postoperative prognosis and the immunolocalization of the markers in the study in liver structures of patients with BA at portoenterostomy.
In patients with BA, at the time of portoenterostomy, the PCK7 ranged between 0.80% and 14.79% (7.06% ± 4.03%), and CA ranged between 5.56% and 47.48% (26.02% ± 9.93%).
There was a significant difference in the PCK7 values between patients with a positive and a negative VEGF A expression in AWs, which were higher in VEGF A-positive patients (P<0.001). A similar fact was observed regarding the VEGFR1 immunolocalization in BDs (P = 0.040). CA and age at portoenterostomy were not different between positive and negative groups for any marker in any liver structure. There were no significant differences in values of the variables associated with postoperative prognosis between patients with positive and negative expression, neither of VEGFR1 and VEGFR2 in AW nor of VEGFR2 in BDs. Table 3 shows the association between the VEGF A-positive immunolocalization in liver structures of patients with BA at the time of portoenterostomy and the variables of BA clinical type and PCK7, using a logistic regression test to specify if the immunolocalization of the marker was actually related to the clinical type or, instead, was determined by the extent of biliary proliferation. The logistic regression showed that the VEGF A-positive immunolocalization in AWs, BDs, and hepatocytes at the time of portoenterostomy was determined by PCK7, not by the BA clinical type (P = 0.031 vs. P = 0.301; P = 0.031 vs. P = 0.136; P = 0.032 vs. P = 0.586, respectively). Table 4 evaluates the relationship between RMED and VEGF A-positive immunolocalization in the liver structures from these groups.
The RMED values in biopsies from BA and IC patients ranged between 0.30 and 3.00 (0.76 ± 0.42). There were differences in the RMED values between the patients with positive and negative VEGF A expression, both in BDs (P = 0.016) and AWs (P = 0.044), higher RMED values occurring in the patients presenting VEGF A positivity in these structures. There was no significant difference in RMED values between patients with negative and positive VEGF A immunolocalization in hepatocytes (P = 0.076).
DISCUSSION
In this study, we observed a characteristic VEGF A immunolocalization in patients with BA, maybe reflecting the etiological aspects of this disease. 17 VEGF A signaling represents the critical rate-limiting step in physiological angiogenesis, acting on endothelial cell mitogenesis and survival, enhancing vascular permeability, causing vasodilation, and stimulating the expression of proteases for extracellular matrix degradation. 21 Besides physiological angiogenesis, VEGF A acts on wound healing, tumors, rheumatoid arthritis, ischemic retinopathy, psoriasis, atherosclerosis, and pulmonary plexogenic arteriopathy. [22] [23] [24] VEGF A is the main angiogenic factor induced by hypoxia. 25 Besides hypoxia, VEGF A activity is induced in situations such as hypoglycemia, acidosis, and inflammation. 26 Recently, polymorphisms of the VEGF A gene in association with BA were described. 27 In a normal liver, VEGF A immunohistochemical expression is observed in centrilobular hepatocytes, 28 BDs, and Kupffer cells, 29 not in arteries. 30 VEGF A immunolocalization is variable according to different liver diseases, and probably affected by the liver zonation as, because of its position, the periportal area is less likely to be exposed to extreme oxygen deprivation than the perivenous area. Hepatocytes are specially affected by reduced oxygen availability in the organ. 31 In models of cirrhogenesis, both by the use of CCl4 and common BD ligation, increasing angiogenesis is associated with increasing VEGF A hepatocytic expression, overpassing pericentral and periportal areas. 32 Hepatocytic VEGF expression is associated with hypoxia induced by the biliary obstructive process, and there is a correlation between ductular reaction and increasing angiogenesis. 33 According to Gaudio et al 28, 34, 35 BDs also express VEGF A in the BD ligation model. In primary biliary cirrhosis, there is VEGF A expression in sinusoidal endothelial cells, at the periphery of the affected portal tracts. 36 In hepatocarcinoma, VEGF A is expressed in tumoral, endothelial, and biliary epithelial cells. [37] [38] [39] In diseases presenting ductal plate malformation, VEGF A and its receptors are expressed in immature biliary epithelium, showing proliferative effects over cholangiocytes and portal vessels. 30 In chronic rejection, the biliary VEGF A expression is associated with angiogenesis and ductular reaction. 29 We evaluated VEGF A immunolocalization in hepatobiliary structures in BA at the times of portoenterostomy and LTx. In explants, VEGF A expression presented a lobular pattern, characteristic of wellestablished cirrhosis, in which hepatocytes suffer from chronically decreased blood supply and oxygenation. However, at portoenterostomy, VEGF A expression was preferentially located in the portal structures, mainly in AWs, besides BDs and hepatocytes. In situations of decreased arterial blood supply to portal structures that depend mostly on the peribiliary vascular plexus, VEGF A expression is showed in the portal biliary system. 31 Our finding is only similar to that observed in the animal model of complete arterial blood deprivation for extrahepatic and intrahepatic BDs developed by Beaussier et al, 17 in which VEGF A positivity occurred both in AW and BD owing to hypoxia/ischemia. What could lead to the portal pattern of VEGF A immunolocalization at portoenterostomy suggestive of hypoxia in portal structures? In BA, there is portal expansion, 6 and the mechanical distortion over vascular structures may induce hypoxia/ischemia. The mechanical distortion may be caused by extracellular matrix deposition that offers resistance to blood flow, inducing hypoxia and VEGF A-positive expression in the portal structures. 40 The expanding biliary mass can also be involved as the extent of biliary proliferation in this study was a determinant for VEGF A positivity in portal space. Biliary proliferation may be associated with VEGF A expression because, whenever necessary, BDs express VEGF A to nourish neocholangiocytes 34 ; in turn, VEGF A produced by cholangiocytes autocrinally stimulates biliary proliferation. 35 In addition, biliary proliferation increases fibrogenesis through epithelial-mesenchymal transition, [41] [42] [43] [44] [45] contributing to hypoxia/ischemia. In this study, the disturbance associated with VEGF A immunolocalization in the portal structures seemed to arise downstream at the site of biliary obstruction: at the porta hepatis, VEGF A was positive in arterial branches, many of which presented a distorted morphology, and also in biliary remnants and hepatocytes. Some researchers observed, by imaging studies, the occurrence of hepatic artery dilation in BA, seemingly associated with a blockade to blood flow at the porta hepatis. [13] [14] [15] [16] Our present data reinforce the existence of an arterial disorder at this site, and suggest the possibility of a secondary ischemic cholangiopathy involving small-sized hepatic arterial vessels. 46 VEGFR1 immunolocalization in hepatobiliary structures was similar in BA and controls, whereas we observed that the VEGFR2 positivity rate was lower in BA than in IC, both in BDs and hepatocytes. VEGFR2 was positive in most patients with IC, but infrequently in patients with BA. This receptor, generally immunolocalized in the endothelial cells and whose expression is stimulated by VEGF A, is a major signal transducer for angiogenesis. 47 Gaudio et al 28, 34, 35 observed that rats undergoing BD ligation presented proliferation of the peribiliary plexus and overexpression of VEGF A and VEGFR2 in BDs, whereas rats undergoing double ligation both at the hepatic artery and at the common BD failed to develop such a vascular proliferation, presenting a decreased number of cholangiocytes positive for VEGF A and VEGFR2, a process leading to cholangiocyte apoptosis. In this study, we have just focused on the immunolocalization of markers, and we are not able to explain whether the characteristic pattern of VEGFR2 expression maybe associated with the tissue levels of VEGFA, which are being presently evaluated by our group. Table 4 shows the relationship between VEGF A immunolocalization in the hepatobiliary structures, notably in BDs, and arterial medial layer thickening. Histopathological alterations of the intrahepatic hepatic artery branches have been observed in BA patients. [48] [49] [50] [51] [52] In 2005, we observed, in BA, the existence of medial thickening of hepatic arterial branches at the time of portoenterostomy, suggestive of vascular remodeling; progression of such a vascular remodeling between portoenterostomy and LTx, and a supposed relationship between medial thickening and the vanishing of BDs. 12 This study suggests that VEGF A expression in BDs and AWs is associated with the medial layer thickening observed in BA. VEGF A is involved with the pathophysiology of pulmonary plexogenic arteriopathy, as its vascular expression is higher in the severe forms of the disease. 53 VEGF A has an indirect role on smooth muscle cell proliferation, by increasing the mitogenic effect of other molecules. 54 In the presence of hypoxia, VEGF A and monocyte chemoattractant protein-1, important regulators of fibrogenesis in pediatric liver disease, 55, 56 act synergistically on vascular smooth muscle cell proliferation. 57 VEGF A participates in liver fibrogenesis 58 and, in the long run, is associated with the development of ascitis 59 and hepatocarcinoma. 38 Presently, angiogenic therapy to modulate the activity of VEGF A and its receptors is being proposed for the treatment of chronic liver diseases. 60 Our findings suggest that VEGF A activity in the portal structures may be involved in progressive cholangiopathy present in BA and, maybe, modulating its expression in these structures can lead to alternative therapeutic options for this disease. In addition, this study encourages the promotion of further analyses assessing the serum levels of VEGF A and its soluble receptors as a method for the graduation of disease severity in these patients, both at portoenterostomy as later, until LTx. 61 In summary, VEGF A in livers from patients with BA at the time of portoenterostomy was preferentially expressed in the portal structures, mainly in AWs, whereas at the time of LTx it was expressed in the parenchyma. VEGF A immunolocalization was dependent on the extent of biliary proliferation. VEGF A was expressed in the porta hepatis of patients with BA, both in biliary remnants and AWs. VEGFR2 was less expressed in BDs and hepatocytes of patients with BA than with IC. VEGF A positivity in BDs and AWs was related to the arterial medial layer thickening. Our findings suggest the existence of an ischemic cholangiopathy in BA.
